Cleveland HeartLab offers innovative, scientifically proven, and medically relevant biomarkers that are predictive of cardiovascular risk. Our novel biomarker technologies are offered through our CAP-accredited and CLIA-certified next-generation clinical reference laboratory. We focus on delivering world-class science right to your doorstep.
Aid clinicians in identifying risk and reducing cardiovascular events.
To be the premier cardiovascular testing provider.
- Evidence-based science and clinical testing
- Superior quality
- Solutions-oriented attitude
- Integrity in all we do
In support of our mission we have three key areas of focus:
We maintain a robust research and development program that partners with leading academic and medical institutions to bring unique biomarker technologies to market. Our first proprietary biomarker – Myeloperoxidase (MPO) – was the result of research and development at the Cleveland Clinic, and received 510(k) clearance from the FDA within 13 months of discovery. We have an expansive, global intellectual property portfolio that includes over 50 issued and pending patents. We consistently bring new, novel biomarkers to the market and maintain an active pipeline in development.
We are the premier providers of inflammation testing to clinicians focused on wellness and prevention. Our proven combination of essential inflammatory biomarkers enables clinicians to measure a patient’s risk across a risk spectrum (long-term, mid-term and near-term), and provides additive and complementary insight beyond standard cholesterol testing alone. Our inflammation testing has over 100 peer-reviewed publications in high impact journals including a Future Cardiology study in 2013 which validates our multi-marker approach. Earlier this year, we presented the first-of-its-kind economic model validating the cost savings with the multi-marker approach for more accurate CVD risk assessment.
We understand that it is our responsibility to help clinicians navigate science, medicine and biomarker testing as these are key to cardiovascular disease prevention. Our Annual Symposium, “Where Inflammation Meets Lipids®” features world-renowned experts and pioneers in the fields of cardiovascular and metabolic disease prevention. We also offer peer-to-peer support to our clinicians which includes reviewing the latest articles on the clinical utility of inflammatory biomarkers or recommendations on standard and advanced lipids, and supporting individual case management.